TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Swedish study of older women found that longer reproductive lifespan and reported menopausal hormone therapy use were associated with more favorable measures of brain vascular health on MRI. The observational findings do not establish that estrogen exposure caused those differences, and the researchers noted limits in participants’ hormone-use histories.
A Swedish cohort study has linked longer reproductive lifespan and menopausal hormone therapy use with lower cerebral small vessel disease burden in older women, while therapy use was also associated with better white matter integrity. The findings, reported in Neurology, describe associations in brain scans and do not show that estrogen exposure caused the differences.
Anna Marseglia, PhD, of the Karolinska Institutet in Stockholm, and colleagues assessed 352 cognitively unimpaired women from Sweden’s 1944 Gothenburg H70 birth cohort. Participants had brain MRI at age 70; 286 returned for an examination five years later. Their mean Mini-Mental State Examination score at baseline was 29.2, and 31% carried the APOE4 genetic variant.
The researchers calculated reproductive lifespan from the age of first menstruation to menopause or ovary removal. It averaged 37.1 years. A longer reproductive span was associated with lower odds of having at least two signs of cerebral small vessel disease: the reported odds ratio was 0.92 (95% confidence interval 0.86 to 0.99). The study’s disease-burden score combined MRI findings including white matter hyperintensities, lacunes, microbleeds and enlarged perivascular spaces.
Reported menopausal hormone therapy use was associated with lower small vessel disease burden (odds ratio 0.41, 95% CI 0.20 to 0.81) and higher white matter integrity (β=0.28, 95% CI 0.06 to 0.50). Among APOE4 carriers, therapy use was associated with greater thickness in cortical regions commonly affected by Alzheimer’s disease (β=0.38, 95% CI 0.01 to 0.76). Women who reported both earlier oral contraceptive use and later menopausal therapy had the lowest measured small-vessel burden and highest white matter integrity in the study’s comparisons. These are statistical associations, not evidence that either treatment prevents brain disease.
Brain Vascular Measures in Older Women
The findings add evidence that reproductive and hormone histories may be relevant to research on brain aging, including vascular changes as well as Alzheimer’s-related measures. Small vessel disease is assessed through changes visible on MRI, and the study connects those measures with differences in women’s reported reproductive timelines and hormone use. It did not test whether the differences translated into fewer dementia diagnoses or better daily functioning.
The results also matter because menopausal hormone therapy remains a subject of medical discussion. The study is not a basis for starting, stopping or selecting treatment: it was observational, involved a relatively small Swedish cohort, and did not establish which therapies, doses or timing might account for the associations. Treatment decisions require individual medical advice and consideration of potential benefits and risks.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Garmin Forerunner 970 GPS Running and Triathlon Smartwatch, 47mm, Carbon Gray DLC Titanium, Black/Whitestone
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
As an affiliate, we earn on qualifying purchases.
Earlier Trials Shape Hormone Debate
Earlier research raised hopes that menopausal hormone therapy might protect against Alzheimer’s disease or cardiovascular illness. But the Women’s Health Initiative Memory Study reported in 2003 that estrogen-plus-progestin formulations increased probable dementia risk among women aged 65 or older. The broader Women’s Health Initiative findings also linked combined treatment to higher breast cancer and heart disease risks, contributing to prominent safety warnings.
In 2026, the U.S. Food and Drug Administration removed the black box warning from menopausal hormone therapy products, according to the source report. That regulatory change does not resolve questions about how treatment affects brain health, nor does it establish that therapy prevents dementia. Other research has examined estrogen-only therapy and the timing of treatment, but those findings are not interchangeable with this Swedish study.
In the cohort, 72.7% reported oral contraceptive use and 60.8% reported menopausal hormone therapy. The investigators also reported that longer estrogen exposure was associated with more stable cortical-thickness and white-matter trajectories over time. The study’s size, age group and specific MRI outcomes limit how broadly those results can be applied.
“The lifetime risk of dementia in U.S. women exceeds that of men.”
— Tracy Madsen, MD, PhD, University of Vermont, in an accompanying editorial
Limits of the Hormone Histories
The findings do not show whether estrogen exposure itself explains the MRI differences. Participants reported their own oral contraceptive and hormone therapy use, which the authors said could involve recall bias or misclassification. The study also lacked detailed information about treatment type and use, limiting comparisons of specific formulations, doses and schedules.
The cohort consisted of women born in 1944 who were cognitively unimpaired at the initial assessment. It is unclear whether the results apply to younger women, other populations or women with cognitive impairment. The report describes associations with MRI measures, not proof of reduced dementia incidence, and the available information does not establish whether the findings hold in larger or more diverse groups.
Further Studies Must Test the Links
The immediate next step is replication in larger studies with more complete records of reproductive timing and hormone treatment, including formulation, dose and duration. Researchers would also need to track clinical outcomes over time, such as cognitive change and dementia diagnoses, to determine whether MRI associations correspond to meaningful differences in health.
Until such evidence is available, the study should be read as a report of observed relationships rather than a treatment recommendation. Marseglia and colleagues’ results support including women’s reproductive and hormone histories in further brain-aging research, but they do not settle whether, when or for whom menopausal hormone therapy might affect dementia risk.
Key Questions
What did the Swedish study find?
In a cohort of 352 women around age 70, longer reproductive lifespan and reported menopausal hormone therapy use were associated with lower cerebral small vessel disease burden. Therapy use was also associated with higher white matter integrity on MRI.
Does the study prove estrogen prevents dementia?
No. It was an observational study of brain imaging measures, and the researchers said the findings do not establish cause and effect. It did not show that estrogen exposure prevents dementia.
What does reproductive lifespan mean here?
The researchers calculated it as the interval between the age at menarche and the age at menopause or ovary removal. The average in this cohort was 37.1 years.
Should women start hormone therapy for brain health?
The study does not support starting or changing treatment for that purpose. It did not establish a protective effect, and treatment decisions should be discussed with a qualified health professional in light of an individual’s circumstances and risks.
Source: medpagetoday.com
